IGFBP5 Antibody

What is IGFBP5 and what cellular functions does it regulate?

IGFBP5 prolongs the half-life of insulin-like growth factors (IGFs) and can either inhibit or stimulate their growth-promoting effects in cell culture systems. It significantly alters the interaction of IGFs with their cell surface receptors . Research has demonstrated that IGFBP5 functions as an important tumor suppressor in melanoma tumorigenicity and metastasis . Additionally, IGFBP5 plays a crucial role in cardiomyocyte survival and functional recovery following myocardial infarction .

What are the molecular specifications of human IGFBP5?

Human IGFBP5 has the following molecular characteristics:

The discrepancy between calculated and observed molecular weights (31 kDa vs. 33 kDa) likely results from post-translational modifications .

What are the validated applications for IGFBP5 antibodies?

IGFBP5 antibodies have been validated for multiple experimental techniques:

The antibody should be titrated in each testing system to obtain optimal results as sensitivity may be sample-dependent .

What species reactivity do IGFBP5 antibodies demonstrate?

Commercial IGFBP5 antibodies typically show:

• Tested Reactivity: Human, mouse

• Cited Reactivity: Human, mouse, rat

When selecting an antibody for your research, confirm the reactivity with your specific species of interest, particularly for comparative studies involving multiple model organisms.

What are the optimal buffer and storage conditions for IGFBP5 antibodies?

For maximum antibody stability and activity:

• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3

• Storage Temperature: -20°C

• Stability: Stable for one year after shipment

• Aliquoting: Unnecessary for -20°C storage

• Special Notes: Some preparations (20μl sizes) contain 0.1% BSA

How should I optimize Western Blot protocols for IGFBP5 detection?

For optimal Western Blot results when detecting IGFBP5:

• Sample Preparation:

  • Use RIPA buffer supplemented with protease inhibitors

  • Load 20-40 μg total protein per lane

• Gel and Transfer Conditions:

  • 10-12% SDS-PAGE gels are recommended

  • Look for bands at approximately 33 kDa

• Antibody Incubation:

  • Primary antibody: Use 1:200-1:1000 dilution

  • Incubate overnight at 4°C for optimal sensitivity

• Positive Controls:

  • SKOV-3 cells, HepG2 cells, or mouse embryo tissue have shown reliable IGFBP5 expression

• Special Considerations:

  • Some antibodies may detect IGFBP5 only under non-reducing conditions

What are the recommended protocols for immunohistochemistry using IGFBP5 antibodies?

For successful IHC staining of IGFBP5:

• Tissue Preparation:

  • Formalin-fixed, paraffin-embedded sections (5 μm thickness)

  • Deparaffinize and rehydrate using standard protocols

• Antigen Retrieval:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

• Antibody Incubation:

  • Primary antibody dilution: 1:50-1:500

  • Positive control tissues: Human breast cancer tissue

• Detection System:

  • Use appropriate species-specific detection systems

  • Include negative controls (omitting primary antibody)

How can I troubleshoot non-specific binding with IGFBP5 antibodies?

When encountering non-specific binding:

• Increase Blocking:

  • Extend blocking time to 2 hours at room temperature

  • Try different blocking agents (5% BSA, 5% non-fat milk, or commercial blockers)

• Optimize Antibody Concentration:

  • Titrate the antibody across the recommended range (1:50-1:500)

  • Begin with more dilute concentrations and increase if necessary

• Modify Washing Steps:

  • Increase number and duration of washes

  • Add 0.1-0.3% Triton X-100 to wash buffers to reduce background

• Consider Sample-Specific Issues:

  • High endogenous peroxidase activity may require additional quenching

  • Tissues with high fat content may benefit from longer deparaffinization

How can I investigate IGFBP5's role in tumor growth and metastasis?

Based on established methodologies:

• Cell Line Models:

  • Generate stable IGFBP5 overexpression and knockdown cell lines

  • A375 and A2058 human melanoma cell lines have been successfully used

• In Vitro Assays:

  • Proliferation: CCK-8 assay

  • Anchorage-independent growth: Colony formation assay

  • Migration: Scratch/wound healing assay

  • Invasion: Transwell invasion assay

• In Vivo Models:

  • Xenograft tumor models to assess tumor growth

  • Tail vein injection for pulmonary metastasis assessment

  • Evaluate tumor size, weight, and metastatic nodules

• Molecular Readouts:

  • EMT markers: E-cadherin and vimentin

  • Stem cell markers: NANOG, SOX2, OCT4, KLF4, and CD133

  • Signaling pathway components: phosphorylation of IGF1R, ERK1/2, p38-MAPK

What methods are effective for studying IGFBP5's role in cardiac function?

To investigate IGFBP5 in cardiac contexts:

• In Vitro Models:

  • Oxygen-glucose deprivation (OGD) in neonatal rat cardiomyocytes (NRCMs)

  • Assess cardiomyocyte proliferation and apoptosis following OGD

• In Vivo Models:

  • Acute myocardial infarction (AMI) in adult mice

  • Heart-specific IGFBP5 knockdown models

  • Evaluate myocardial apoptosis and cardiomyocyte proliferation

• Signaling Pathway Analysis:

  • Focus on the IGF1 receptor (IGF1R)/protein kinase B (PKB/AKT) pathway

  • Assess phosphorylation status of key signaling proteins

• Functional Assessment:

  • Cardiac remodeling markers

  • Echocardiography for functional recovery assessment

  • Histological analysis of fibrotic remodeling

How can I assess the prognostic value of IGFBP5 in human cancers?

For rigorous prognostic assessment:

• Clinical Sample Analysis:

  • Perform IHC staining on patient tumor samples

  • Use established grading systems (e.g., IHC 3+, 2+, 1+, 0-)

  • Compare expression in primary tumors, metastatic tissues, and normal tissues

• Bioinformatic Approaches:

  • Analyze data from cancer genomic databases (TCGA, CGGA)

  • Generate Kaplan-Meier survival curves

  • Create diagnostic receiver operating characteristic (ROC) curves

  • Develop nomogram models

• Correlation Analysis:

  • Associate IGFBP5 expression with:

    • Immune cell infiltration

    • Immune checkpoint genes

    • Clinicopathological features

• Validation Methods:

  • Quantitative real-time PCR (qRT-PCR) on clinical samples

  • Western blot analysis for protein-level validation

  • Multi-cohort validation using independent patient datasets

How do I interpret seemingly contradictory roles of IGFBP5 across different cancer types?

The context-dependent functions of IGFBP5 require careful interpretation:

• Tumor Suppressor Role:

  • In melanoma, IGFBP5 overexpression inhibits proliferation, anchorage-independent growth, migration, and invasion

  • IGFBP5 suppresses epithelial-mesenchymal transition (EMT) and decreases stemness marker expression in A375 melanoma cells

• Tumor Promoting Role:

  • In glioma, IGFBP5 levels increase with malignancy grade

  • Higher IGFBP5 expression predicts poor outcomes in glioma patients

• Methodological Considerations:

  • Compare experimental models (cell lines, animal models)

  • Consider tissue specificity and microenvironmental factors

  • Evaluate different domains of IGFBP5 which can exert distinct effects on tumorigenicity

• Reconciliation Approach:

  • Examine receptor availability (IGF1R) in different tissues

  • Assess interaction with other binding partners

  • Consider post-translational modifications that may alter function

What explains the heterogeneous expression patterns of IGFBP5 across clinical samples?

When analyzing variable IGFBP5 expression:

• Expression Patterns in Melanoma:

  • Higher expression in melanoma samples compared to normal pigmented nevus samples

  • Mean IHC score: 1.8 for melanoma vs. 0.4 for pigment nevus tissues

  • Strong staining in primary melanoma but weaker in metastatic tissues

• Cell Line Variations:

  • High expression in A2058 and UACC903 melanoma cells

  • Low expression in HEMn-LP normal melanocytes and A375 melanoma cells

• Interpretation Framework:

  • Consider disease stage-specific regulation

  • Evaluate genetic and epigenetic heterogeneity

  • Assess microenvironmental influences

  • Recognize technical variables in detection methods

• Validation Approach:

  • Use multiple detection methods (IHC, qRT-PCR, WB)

  • Include larger sample sizes

  • Stratify results by clinicopathological parameters

What novel approaches could further elucidate IGFBP5's molecular mechanisms?

Emerging methodologies for IGFBP5 research:

• Single-Cell Analysis:

  • Single-cell RNA sequencing to identify IGFBP5-expressing cell populations

  • Spatial transcriptomics to localize IGFBP5 expression within tissue architecture

• Protein-Protein Interaction Studies:

  • Proximity ligation assays to visualize IGFBP5 interactions in situ

  • Co-immunoprecipitation combined with mass spectrometry to identify novel binding partners

• CRISPR-Based Approaches:

  • CRISPR activation/interference to modulate IGFBP5 expression

  • CRISPR base editing to introduce specific mutations in IGFBP5 or its regulatory elements

• Integrative Multi-Omics:

  • Combine transcriptomics, proteomics, and metabolomics to map IGFBP5's influence on cellular processes

  • Network analysis to position IGFBP5 within broader signaling pathways

How can IGFBP5 research be translated into clinical applications?

Bridging laboratory findings to clinical utility:

• Diagnostic Applications:

  • Develop standardized IHC protocols for IGFBP5 detection in pathology

  • Establish cutoff values for prognostic stratification

  • Create multiparameter panels including IGFBP5 and related molecules

• Therapeutic Targeting:

  • Design peptide mimetics of IGFBP5's functional domains

  • Develop antibodies targeting specific IGFBP5 epitopes

  • Create small molecule modulators of IGFBP5-IGF1R interactions

• Patient Stratification:

  • Identify patient subgroups that might benefit from IGFBP5-targeted therapies

  • Develop companion diagnostics for treatment selection

  • Integrate IGFBP5 status into existing clinical decision frameworks